Non Odontogenic Tumors: Dental Science
Non Odontogenic Tumors: Dental Science
Non Odontogenic Tumors: Dental Science
▪ Ectoderm (outer).
▪ Endoderm / Entoderm (inner).
▪ Mesoderm, develops between the ectoderm and
the endoderm.
DERIVATION OF TISSUES
• The body tissues and organs develop from three primary germ layers
• The tissues derived from the ectoderm are:
– Epithelial tissue (epidermis)
– Modified epidermal tissue
– Nerve tissue, salivary glands,
– Epithelial tissue and mucous glands of the nose and mouth.
• Epithelial tissue derived from ectoderm is generally squamous epithelium
Lymphoma
• Lymphomas develop in the glands or nodes of the lymphatic system
CANCER DIAGNOSIS
• The diagnosis of cancer entails an attempt to..
▪ Accurately identify the anatomical site of origin of the
malignancy
▪ The type of cells involved
• Surgery
• Radiotherapy
• Chemotherapy
• Hormonaltherapy
• Targetted therapy
Oral Cavity Anatomy Component
• The oral cavity extends from vermilion border of
lips to the plane between junction of the hard
palate and soft palate
• Lips : upper and lower lip
• Oral cavity
• Buccal mucosa
• Tongue
• Ginggiva
• Retromolar area
• Flour of mouth
• Hard palate
NON ODONTOGENIC TUMORS
Benign :
• Ossifying fibroma - Juvenile ossifying fibroma
• Fibro-osseous tumors
• Osteoma
• Osteoid osteoma and osteoblastoma
• Desmoplastic fibroma
• Chondroma
• Giant cell tumor
• Langerhans cell disease
Malignant :
• Squamous Cell Carcinoma HNSCC
• Osteosarcoma
• Chondrosarcoma
• Malignant fibrous histiocytoma
• Malignant peripheral nerve sheath tumor
• Ewing’s sarcoma
• Burkitt’s lymphoma
• Multiple myeloma
• Metastatic carcinoma
Ossifiying Fibroma
• Etiology
– Unknown
• Predilection
– Onset between 5 and 15 years of age
– Maxilla and paranasal areas predominate
• Clinical appearance
– Rapid growth over several weeks
– Expansile lesion of bone, Cortices intact
– May produce deformity, malocclusion, dysfunction
– Well-defined radiolucency
Ossifiying Fibroma
• Differential Diagnosis
– Osteosarcoma
– Central giant cell granuloma
– Odontogenic tumor
• Treatment
– Wide local excision
• Prognosis
– Recurrence rate of 30 to 50%
Osteoma
• Etiology
– Unknown, May be a component of Gardner’s syndrome
• Predilection
– Mostly mandibula
– Rare Maxilla and sinus frontoethmoid
• Clinical appearance
– Sporadic form, may be Multiple
– Well-defined radioopacity
Osteoma
• Differential Diagnosis
– Ossifying fibroma
– Osteoblastoma
– Focal sclerosing osteitis
• Treatment
– Wide local excision
• Prognosis
– Excellent, Low recurrence rate
Osteoid Osteoma
• Predilection
– Young age, under 30
– Rarely in jaw, most common in femur and tibia
• Clinical appearance
– Soft tissue mass in cortex and may produce swelling of
overlying tissue
– intense pain depend to size
– Less than 2 cm, more than 2 cm Osteoblastoma
Osteoid Osteoma
• Differential Diagnosis
– chronic suppurative osteomyelitis
• Treatment
– Surgical excision
• Prognosis
– Excellent, Low recurrence rate
Chondroma
• Central benign cartilaginous tumor
• Predilection
– Anterior portion of the maxilla, condyle and coronoid
process are the most common
– Rarely in jaw
• Clinical appearance
– Slow growing tumorproducing destruction and exfoliation
of teeth
– Painless
– Cyst like radiolucencies
Chondroma
• Treatment
– Surgical excision
• Prognosis
– Excellent, Low recurrence rate
Giant Cell Tumor
• Etiology
– Unknown, May be a component of Gardner’s syndrome
• Predilection
– Young, Female
– Ginggiva
• Clinical appearance
– Small, often lobulated
– Smooth-surfaced or pebble-surfaced
– Painless nodule
• Treatment
– Conservative surgical excision
NON ODONTOGENIC TUMORS
Benign :
• Ossifying fibroma - Juvenile ossifying fibroma
• Fibro-osseous tumors
• Osteoma
• Osteoid osteoma and osteoblastoma
• Desmoplastic fibroma
• Chondroma
• Giant cell tumor
• Langerhans cell disease
Malignant :
• Squamous Cell Carcinoma HNSCC
• Osteosarcoma
• Chondrosarcoma
• Malignant fibrous histiocytoma
• Malignant peripheral nerve sheath tumor
• Ewing’s sarcoma
• Burkitt’s lymphoma
• Multiple myeloma
• Metastatic carcinoma
RULES of SARCOMA
• Behavior
• Diagnosis
– Grading
• Treatment
– Surgery
Osteosarcoma
• Etiology
– Associated with pre-existing bone
– Mutation/amplification of p53, c-myc, c-JUN, c-fos, MOM2,
CDK4, SAS
• Predilection
– Onset between 5 and 15 years of age
– Mandibula > Maxilla
• Clinical appearance
– Swelling, Pain, paresthesia, trismus, sinus obstruction
– Tooth mobility (vertical)
– Jaw mass may be ulcerated
Osteosarcoma
• Treatment
– Radical ablative surgery
• Hemimandibulectomy
• Partial maxillectomy ± orbital exenteration
– Adjuvant chemotherapy/radiotherapy
• Prognosis
– Survival ranges from 12 to 58% at 5 years
– Mandibula better than maxila
Chondrosarcoma
• Malignant tumor characterized by the formation of
cartilage, but not of bone
• Predilection
– Wide range of age, peak 30-40
– Maxilla (anterior) more freqwent than mandibula
(molar premolar)
• Clinical appearance
– Slow-growing, painless mass or swelling
– Minority cause pain
– Nasal symptoms, visual disturbances, and sensory
alterations
– Osteolytic lesion with poorly defined borders
Chondrosarcoma
• Treatment
– Radical ablative surgery
– Adjuvant Radiotherapy (not survival, Longterm benefit )
• Prognosis
– Survival ranges from 32 to 81% at 5 years
– Mandibula better than maxila
Ewing’s Sarcoma
• Etiology
– Unknown
– Chromosomal translocations
• Predilection
– 60% in males; over 95% in those under 20 years
– Second most common bone tumor of children
• Clinical appearance
– Chiefly in bone and soft tissues
– Highly malignant
– Pain, numbness, and swelling often early complaints
– Diffuse, irregular, lytic bone lesion, Cortical expansion
Ewing’s Sarcoma
• Differential Diagnosis
– Osteosarcoma
– Lymphoma
– Peripheral neuroectodermal tumor
• Treatment
– Radiation and multiagent chemotherapy
• Prognosis
– 54 to 74% 5-year survival rate in localized osseous form
– Late relapse not uncommon
Malignant Fibrous Histiocytoma
• Malignant neoplasm of soft tissue and bone, which is
composed of fibroblasts
• Clinical appearance
– Rarely in jaw
– Highly malignant, aggresive tumor
– Propensity for recurence and Lung metastasis
• Treatment
– Radical ablative surgery
– Adjuvant chemotherapy/radiotherapy
Burkitt’s Lymphoma
• High-grade, non-Hodgkin’s B-cell lymphoma
• Activation c-myc oncogene through chromosomal
translocations
• Predilection
– 3 - 8 years of age
– Jaw involvement is common and progress rapidly as facial
swelling and huge exophitic mass
• Treatment
– Intensive chemotherapy resulted a dramatic improvement
– Survival rate 70-85%, but deadly if untreated
Metastatic Cancer
• Predilection
– Usually from lung, breast, prostate, colon, kidney
– Only 1%, sometime underestimate
• Clinical appearance
– Swelling and pain
– As primary tumor pattern
• Treament
– Combination of chemo and radiotherapy
• Prognosis
– Poor
Squamous Cell Carcinoma
• 90% SCC:..................HNSCC
Well/Moderate/Poorly/Undiff
Exophytic, Ulcerative, Infiltrative, Verucous
• Adeno Carcinoma
malignant minor salivary gland tumors
Squamous Cell Carcinoma
Site Predilection
⦿ Tongue (35%)
⦿ Floor of mouth (30%)
⦿ Lower alveolus (15%)
⦿ Buccal mucosa (10%)
⦿ Upper alveolus/hard palate (8%)
⦿ Retromolar (2%)
⦿ Lips
○ lower 93%,
○ upper 5%,
○ commissure 2%
Squamous Cell Carcinoma
Risk Factor
• Heavy tobacco
• Alcohol.
• Syphilis
• Viruses (EB, HSV, HPV)
• Neglect of oral dental hygiene
• Chronic infection
• Unfit dentures
• Lichen planus
• Immunosuppression
• Malnutrition
• Clinical appearance
– Premalignant lesions:
• Leucoplakia
• Hyperplasia
• Erythroplakia
• Dysplasia
UICC/AJCC STAGING SYSTEM FOR ORAL CANCER 2002
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1, T2 N1 M0
T3 N1 M0
Stage IV A T1, T2, T3 N2 M0
T4a N0, N1, N2 M0
Stage IV B Any T N3 M0
T4b Any N M0
Stage IV C Any T Any N M1
Oral tongue cancer
Squamous Cell Carcinoma
• Treatment
– Radical ablative surgery
• Radical excision for Primary tumor
• Neck dissection for node metastasis
– Adjuvant chemotherapy/radiotherapy
Follow Up
• All cancer treatment should be followed in the
right way and right time
• Be the first to know the recurrent tumor
• What should be to followed up?
– treatment of the cancer
– the progress of the entire cancer’s patient
– survival
Prevention